Clinical Trial Search

Primary: Percent Change From Baseline in PASI at Week 12 — 85.7; 86.3 Percent change

Primary: Change in Frequency of Symptomatic RP Attacks — -11.47; -12.73 Number of RP attacks per week — p=0.4210

Primary: Morphine Milligram Equivalents Used During Inpatient Stay — 10.8; 8.8 morhpine milligram equivalents

Primary: Percentage of Participants With Juvenile Idiopathic Arthritis American College of Rheumatology (JIA ACR) 30 Response — 100; 100; 100; 100 Percentage of Participants

Primary: Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) — 0.5; 0.3; 1.0; 0.6 score on a scale

Primary: Major Cardiovascular Adverse Events (MACE) — 156; 118 number of adjudicated events — p=< 0.025

Primary: Progression-free Survival (PFS) — 9.3; 7.4 months — p=0.0006

Primary: ΔHbA1c — -1.8; -1.6 percentage of HbA1c

Primary: Change From Baseline in Hb to the Average Over the Primary Evaluation Period (PEP) (Weeks 20 to 26) — 0.07; -0.19; 0.34 Grams per deciliter (g/dL)

Primary: Change in Maximal VO2 From Baseline to Week 26 Using Last Observation Carried Forward (LOCF) — -0.23; -0.89 mL/kg/min — p=0.092

Primary: Percentage of Participants Achieving Complete Response in 5-FU Arm and Observation Arm Using ITT Population — 5; 9 Participants — p=0.1877

Primary: Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks Expressed in Milliliter (mL) — -191.89; -85.32 Milliliter/year

Primary: Overall Survival — 17.6; 15.5 Months — p=0.2840

Primary: Clinical Reaction — 0; 0; 12; 8 Participants

Primary: Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 (Defined as at Least 75% Improvement in PASI) — 83.3; 85.7; 85.2; 92.3 percentage of…